Through Gil Martin
Published on June 21 21 at 13:52
In Montpellier, the biopharmaceutical company NFL Biosciences is developing botanical drugs for the treatment of dependencies and addictions. This start-up has notably developed a novel approach to smoking cessation using a botanical drug, approved for a Phase II / III clinical trial …
Quitting smoking: a natural alternative
This treatment, called NFL-101, uses a natural product, composed of natural proteins extracted from standardized tobacco leaves and devoid of nicotine. A revolutionary treatment that could well conquer the planet: “We wish to offer smokers who wish to quit a natural, safe, long-term effective alternative, short and personalized administration”, indicates Bruno Lafont, biochemical engineer, founder and CEO NFL Biosciences delegate.
“The results: strong reduction in the desire to smoke, successful long-term quitting attempts, strong reduction in daily consumption, and this without showing any toxicity”
NFL-101 is derived from a subcutaneous desensitization treatment originally developed by the Pasteur Institute against allergies in workers in tobacco factories: “We have developed a standardized version of this treatment for pharmaceutical use”, specifies the manager
Phase-1 pre-clinical studies
NFL-101 is given as two injections under the skin, given one week apart when trying to stop. This treatment has been the subject of preclinical and Phase I studies “which have confirmed a strong reduction in the desire to smoke, successful long-term quit attempts, or a sharp reduction in daily consumption,” and this without showing any toxicity, ”adds Bruno Lafont.
At least 5 M € expected on the stock market
To conquer the world market, NFL Biosciences intends to acquire the necessary resources (human and financial) to ensure the success of NFL-101. The engineer therefore confirms the launch of the IPO of the company which wants to integrate Euronext Growth Paris. “We are targeting 5.26 M €, a fundraising that can be increased to 8 M €”, he indicates.
The latter took his precautions: “NFL-101 is a patented French innovation, solidly protected internationally by two families of patents”, he explains: “Beyond NFL-101, our company has projects for the development of botanical drugs for the treatment of cannabis use disorders and alcoholism ”.
What will the IPO be used for?
NFL Biosciences explains why this step is necessary. The expected fundraising will allow biotech to:
-accelerate its international development;
– to carry out the costly Phase II / III study of the drug candidate NFL-101 (“drug already approved in Australia”, recalls Bruno Lafont;
-to recruit to strengthen the organization;
-to develop the NFL-201 and NFL-301 programs for the treatment of addiction to cannabis and alcohol.
.
Has this article been useful to you? Note that you can follow Métropolitain in the Mon Actu space. In one click, after registration, you will find all the news of your favorite cities and brands.
